"Buzz on the Street" Show: Endonovo Therapeutics (OTCQB: ENDV) SofPulse® Sales to Medical Center | Financial Buzz

“Buzz on the Street” Show: Endonovo Therapeutics (OTCQB: ENDV) SofPulse® Sales to Medical Center

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center.”

Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announced initial sales of SofPulse® units into a VA hospital in Texas.

About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com.

The medical technology industry includes various segments such as instruments, apparatuses, and machines that are used in the prevention, diagnosis or treatment of illness or disease. Additionally, they can also aid in detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purposes. The medical device industry often operates in conjunction with several other industries such as microelectronics, telecommunications, instrumentation, biotechnology, and software development. These cross industrial collaborations have led to significant technological advances in recent years, including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Innovation fuels the medical device market, therefore, major investment in Research and Development is part of the formula for many companies involved; as discovering better ways to treat and diagnose medical conditions is key to success, especially when considering patient life expectancy and the increasing aging populations globally.

And according to data, the United States is still the largest medical device market, with a value of USD 156 Billion, which is 40% of the global industry in 2017. Research provided by SelectUSA, a U.S. government-wide program led by the U.S. Department of Commerce, projects that by 2023, the medical device market is expected to grow to USD 208 Billion

An example of the innovative progress in the medical devices market can be seen in the subsector of Electroceuticals, a new category of therapeutic agents which act by targeting the neural circuits of organs. Electroceutical therapy works by mapping the neural circuitry and delivering neural impulses to these specific targets. The impulse is administered via an implantable device. ScienceDirect describes Electroceuticals is a recently coined term that broadly encompasses all bioelectronic medicine. It includes any type of electrical stimulation to affect and modify functions of the body; neural implants such as cochlear implants, retinal implants or spinal cord stimulators for pain relief but also cardiac pacemakers and implantable defibrillators. Recently, the field has expanded to include deep brain stimulation and the electrical stimulation of the vagus nerve, historically cited as the pneumogastric nerve, which interfaces with the parasympathetic control of the heart, lungs, and digestive tract. Increasing investments in the development of advanced bioelectric medicine is a major factor supporting the growth of the electroceuticals market. And the global electroceuticals/bioelectric medicine market size is expected to reach USD 28.5 Billion by 2026 while expanding at a CAGR of 7.4% according to a report by Grand View Research, Inc.

For more information, please visit: Endonovo Therapeutics, Inc.

For more corporate news on Endonovo Therapeutics, Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For endonovo therapeutics, inc., financial and corporate news dissemination, FinancialBuzz.com has been compensated four thousand dollars by meridian ventures. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.